Amylyx Pharmaceuticals Inc. Common Stock (AMLX)
Stock · NASDAQ · Health Care
$26.34as of 10/16/2026
Price chart
Active signals
AMLX Signal Track Record
How signals performed across all stocks →What AMLX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | +1.0% | 51% | August 19, 2026 |
| Bollinger Band Breakout | 22 | +5.6% | 59% | August 18, 2026 |
| Bollinger Band Breakdown | 18 | -1.5% | 44% | September 25, 2026 |
| 200-Day Moving Average TouchActive now | 7 | +15.1% | 71% | June 11, 2026 |
| Any 20-session window (baseline) | +0.6% | 51% |
Computed by MarketWall from daily closing prices since October 24, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AMLX
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsu…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 136
- Website
- www.amylyx.com/
Fundamentals
- 1-day range
- $26.06$27.53
- Market cap
- $2.69B
- P/E (trailing)
- —
- P/E (forward)
- -23.56
- EPS (trailing)
- $-1.43
- Dividend yield
- —
- Beta
- -0.10
- Avg. volume
- 2.35M
Forecasts
11 analyst ratings
Amylyx Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- AMLXAmylyx Pharmaceuticals Inc. Common Stock$26.34▼ 4.74%Market cap $2.69BP/E —$10.83$41.14
- SUPNSupernus Pharmaceuticals Inc. Common Stock$37.88▼ 4.27%Market cap $2.72BP/E —$39.36$59.68
- TRVITrevi Therapeutics Inc. Common Stock$11.88▼ 1.90%Market cap $2.63BP/E —$9.28$20.22
- NRIXNurix Therapeutics Inc. Common stock$24.42▼ 2.12%Market cap $2.62BP/E 9.25$9.14$28.23
- PBHPrestige Consumer Healthcare Inc. Common Stock$49.92▲ 1.46%Market cap $2.58BP/E 13.50$42.62$71.07
- RAREUltragenyx Pharmaceutical Inc. Common Stock$14.54▼ 4.15%Market cap $2.54BP/E —$12.73$39.89
- NKTRNektar Therapeutics Common Stock$35.78▼ 5.14%Market cap $2.48BP/E —$33.4$109
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AMLX Amylyx Pharmaceuticals Inc. Common Stock | $2.69B | — | $26.34 | ▼ 4.74% | $10.83$41.14 |
| SUPN Supernus Pharmaceuticals Inc. Common Stock | $2.72B | — | $37.88 | ▼ 4.27% | $39.36$59.68 |
| TRVI Trevi Therapeutics Inc. Common Stock | $2.63B | — | $11.88 | ▼ 1.90% | $9.28$20.22 |
| NRIX Nurix Therapeutics Inc. Common stock | $2.62B | 9.25 | $24.42 | ▼ 2.12% | $9.14$28.23 |
| PBH Prestige Consumer Healthcare Inc. Common Stock | $2.58B | 13.50 | $49.92 | ▲ 1.46% | $42.62$71.07 |
| RARE Ultragenyx Pharmaceutical Inc. Common Stock | $2.54B | — | $14.54 | ▼ 4.15% | $12.73$39.89 |
| NKTR Nektar Therapeutics Common Stock | $2.48B | — | $35.78 | ▼ 5.14% | $33.4$109 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Our Pick Of The Best Growth Stocks In September 2026Yahoo · 9/25/2026
- Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic ForumYahoo · 9/23/2026
- Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/16/2026
Insider Activity
Insider Actions →- Mazzariello Gina · September 10, 2026 · Sale11 @ $33.34
- Mazzariello Gina · September 10, 2026 · Sale9.5K @ $32.46
- Cohen Joshua B · September 10, 2026 · Sale919 @ $33.15
- Cohen Joshua B · September 10, 2026 · Sale29.5K @ $32.16
- Klee Justin B. · September 10, 2026 · Sale1.4K @ $33.16
- Klee Justin B. · September 10, 2026 · Sale29.0K @ $32.13
- Bedrosian Camille L · September 10, 2026 · Sale2.1K @ $33.09
- Bedrosian Camille L · September 10, 2026 · Sale7.9K @ $32.21
- FRATES JAMES M · September 10, 2026 · Sale1.0K @ $33.23
- FRATES JAMES M · September 10, 2026 · Sale9.8K @ $32.27
- Firestone Karen · August 31, 2026 · Option Exercise25.0K @ $1.76
- Klee Justin B. · August 18, 2026 · Grant60.0K
- Mazzariello Gina · August 18, 2026 · Grant21.3K
- Cohen Joshua B · August 18, 2026 · Grant60.0K
- Bedrosian Camille L · August 18, 2026 · Grant22.8K
Institutional Ownership
March 31, 2026
- Total shares held
- 112.87M
- Total value held
- $1.56B
- Institutional holders
- 167
- Unknown16.63M
- Unknown8.83M
- Unknown8.28M
- Unknown6.24M
- Unknown5.65M
- Unknown4.99M
- Unknown4.35M
- Unknown4.14M
- Unknown3.56M
- Unknown3.19M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Amylyx to Present Phase 3 Avexitide Data at ObesityWeek 2026
Amylyx Pharmaceuticals is scheduled to present topline data from its Phase 3 LUCIDITY trial for avexitide at the ObesityWeek 2026 annual meeting. The data will focus on the drug's efficacy and safety in treating post-bariatric hypoglycemia. This upcoming presentation is a key catalyst for the company, as it provides new clinical evidence for a major therapeutic area.
Amylyx to Present Phase 3 Avexitide Data at ObesityWeek 2026. Amylyx Pharmaceuticals is scheduled to present topline data from its Phase 3 LUCIDITY trial for avexitide at the ObesityWeek 2026 annual meeting. The data will focus on the drug's efficacy and safety in treating post-bariatric hypoglycemia. This upcoming presentation is a key catalyst for the company, as it provides new clinical evidence for a major therapeutic area.